THE USE OF INOSITOLTRISPHOSPHATE FOR THE PREPARATION OF MEDICAMENTS

Abstract: The present invention relates to the use of inositoltrisphosphate (IP3) for the preparation of a medicament effective as an analgesic.

Description: THE USE OF INOSITOLTRISPHOSPHATE FOR THE PREPARATION OF MEDICAMENTS The present invention relates to the use of at least one isomer of inositoltrisphosphate (IP 3 ) for the preparing of a medicament effective as an analgesic. Many diseases and medical procedures are characterized by the sense of pain in different ways for the patient. For example during and after surgical operations the manifestation of pain is high. The same is true for many disorders related to trauma. Thus e.g. burn patients suffer great pain directly after an accident but also during the recovery period. Pain is also mainfested in most inflammatory conditions and in association tumour-related diseases or treatment of those. Different therapeutics are used in order to achieve an analgetic or anaesthetic effect. Various types of local anaesthetics are utilized to abolish the sensation of pain to a limited area of the body around the site of its application. Other drugs such as opioids, for example morphine, are used for reducing severe pain related to surgical operations. Another type of pharmaceuticals used to reduce pain are sedative agents such as barbiturates and benzodiazepines. Many of these drugs have side effects such as depressant action on respiration and circulation and are producing nausea and vomiting, which limit their use to many groups of patients. Furthermore many of the used drugs give hypnotic effects which are undesirable for the patient. Nonsteroidal anti-inflammatory drugs are used to treat pain and inflammation. This class of compounds works by preventing the synthesis of prostaglandins and side-effects such as damage to the gastic mucosa often appear. According to the present invention it has surprisingly become possible to reduce pain without, sedative effects by the use of at least one isomer of inositoltrisphosphate (IP 3 ) for the preparing of a medicament effective as an analgesic. In preferred embodiments of the invention the medicament is intended to be used for preventing, alleviating and combatting pain. The medicament can be used for example in the following conditions in order to reduce pain: Tissue damage induced mechanically or chemically such as burns, trauma i.e. wounds or injuries caused by physical damage. Injuries following surgery or operations. Conditions related to tumours. Inflammatory conditions such as joint inflammations. The medicament can also be effective in other disorders or conditions where reduction of pain is desirable. The medicament exerts significant analgesic effects without showing any side-effects and without any sedative effects which is very beneficial for the patient. From the European Patent No 179439 a pharmaceutical composi¬ tion comprising as a pharmaceutically active ingredient at least one isomer of inositoltrisphosphate is known. In said patent the effect of this pharmaceutical composition is shown for different areas, such as platelet aggregation. The production of IP and the isolation of the different isomers thereof are disclosed in the US patent No 4.777.134. The IP isomers can also be produced by synthetic methods, chemically or enzymatically, starting with e.g. inositol and a phosphorus source. Furthermore, microbiological production methods including hybrid DNA-techniques of IP_ are also suitable. The structure of IP and the different isomers thereof are disclosed in the US patent No 4.735.936 and the US patent No 4.797.390. It is suitable that the medicament used according to the invention exists in unit dosage form. Tablets, granules or capsules are suitable administration forms for such unit dosage. Futhermore, tablets and granules can easily be surface treated such as to provide an enteric coating to prevent an uncontrolled hydrolysis in the stomach and to bring about a desired absorption in the intestine. Other suitable administration forms are slow release and trans- dermal administration. A usual pharmaceutically acceptable additive, excipient and/or carrier can be included in the medicament. The tablets or granules can also contain a disintegrant which causes the tablets or the granules, respectively, to disintegrate easily in the intestine. In certain cases, especially in acute situations, it is preferable to use the unit dosage in the form of a solution for intravenous administration. In other situations suspensions comprising the compound can be preferably used as administration form. The medicament can also consist as such of IP 3 solely without any additive, excipient or carrier. If desired, the medicament can be free of other inositol phosphates, IP , IP„, IP 4 , IP-- and IPg. Accordingly, the mixture of IP isomers can have a purity of 90-100 % or preferably 95-100 %. Alternatively, the medicament can consist of or comprise one or more specific IP_ isomers, each present in substantially pure form. Thus, the different isomers can be isolated from each other in substantially pure form, which means that they have a purity of 80-100 %, such as 82-100 % or 85-100 %, pre¬ ferably 90-100 %. Since the isomers can be produced in pure form they can be mixed in any proportion, of course. The medicament can consist of IP , wherein said IP is provided by at least one of IP fi . IP,- or IP. and a degradative substance such as an enzyme suitable to form IP . It is in most cases suitable that the IP -isomer or isomers used for the preparing of the medicament according to the invention are present in salt form in order not to affect the mineral balance negatively. The salt should preferably consist of a sodium, potassium, calcium, zinc or magnesium salt or a micture of two or more of these salts. For the above mentioned reasons it is also an advantage if the medicament contains a surplus or an extra addition of at least one pharmaceutically acceptable salt of calcium, zinc or magnesium with a mineral acid or organic acid. This is especially valuable for elderly persons who are often deficient in these minerals. For administration to human patients appropriate dosages can routinely be determined by those skilled in this art by extension of the results obtained in animals at various dosages. The preferred dosage for humans falls within the range of 0.1 to 1000 mg, especially 0.1-200 mg IP /day/kg body weight. In animal experiments, no toxic effects were seen after administration of very high doses of IP 3. 160 mg/kg body weight by intraperitoneal injection to mice. The medicament usually contains 0.01-1.5 g, such as 0.05-1.3 g or preferably 0.1-1 g of IP per unit dosage. The composition used according to the present invention contains at least one, sometimes two or more of the following substances, which correspond to the essential IP -isomer or isomers mentioned above: D-myo-inositol-1.2.6-trisphosphate of the formula n -Xz * where X is hydrogen, at least one univalent, divalent or multivalent cation, or a mixture thereof, n is the number of ions, and z is the charge of the respective ion; Myo-inositol-l.2.3-trisphosphate of the formula where X, n and z have the above mentioned meaning; L-myo-inositol-1.3.4-trisphosphate of the formula where X, n and z have the above mentioned meaning. In each of the above formulas n ranges between 6 to 1 inclusive and z ranges from 1 to 6 inclusive. Preferably, n is between 3 to 6 inclusive and z is 3, 2 or 1. Of the above isomers D-myo-inositol-1.2.6-trisphosphate is preferred. Other inositol trisphoshate isomers that may be utilized in the present invention as the active IP ingredient in the composition have the structural formula One group of inositol trisphosphate compounds is defined by the structural formula (I) where three of R , R , R , R , R and R are hydroxy1 and the remaining three are phos¬ phate and R , R , R , R , R g and R are hydrogen. Another group of inositol trisphosphates is defined by the structural formula (I) where three of Rl. , R_ z>, RΌ-., R_/, R Q y and R are hydroxyl and the remaining three are phosphate and R 2 , R 4 , R 5 , R 8 , R χ0 and R χl are hydrogen. Still another group of inositol trisphosphates is defined by the structural formula (I) where three of R., RJ, R , Ro, RXU and R are hydroxyl and the remaining three are phosphate and R 2' R 4' R 6' R 7' R and R are hydrogen. Yet another group of inositol trisphosphates is defined by the structural formula (I) where three of R , R , R R R and R _ are hydroxyl and the remaining three are phosphate and R , R , R , R ? , R 1Q and R are hydrogen. Still yet another group of inositol trisphosphates is defined by the structural formula (I) where three of R , R 3 , R g , g , R n 9 and R_1._2 are hydroxyl and the remaining three are phosphate and R , R , R 5 , R_, R 1Q and R are hydrogen. Even still another group of inositol trisphosphates is defined by the structural formula (I) where three of R^ R 3 , Ro., R_/, R1.U. and R 1_..2_. are hydroxyl and the remaining three are phosphate and R_, R , R 5 , R„, R g and R are hydrogen. Even yet another group of inositol trisphosphates is defined by the structural formula (I) where three of R , R , R , R , R and R are hydroxyl and the remaining three are phosphate and R 2 , R , R g , R_, R g and R are hydrogen. Finally, another group of inositol trisphosphates is defined by the structural formula (I) where three of R , R , R , R , R n y and R.i. are hydroxyl and the remaining three are phosphate and R , R , R , R , R and R are hydrogen. Particular inositol trisphosphate compounds within the con¬ templation of the above formula include compounds having the structural formula (I) where R R and R _ are phosphate, R , R 3 and R are hydroxyl and R 2 , R 4 , R g , R 8 , R g and R χ2 are hydrogen; , R and R χι are phosphate, R 3 , R-. and R are hydroxyl and R 2 , R 4 , R 6 , R 8 , R g and R 12 are hydrogen; R , R and R are phosphate, R 5 , R ? and R 1Q are hydroxyl and R, R 4 , R 6 , R 8 , R g and R χ2 are hydrogen; R. R 5 and R are phosphate, R , R- 0 and R are hydroxyl and R 4 , R 6 , R 8 , R g and R χ2 are hydrogen; R and R are phosphate, R , R 5 and R are hydroxyl and R, R 4 , Rg, R g , R g and R 12 are hydrogen; R, R and R are phosphate, R , R 5 and R„ are hydroxyl and R, R 4 , R g , R , R and R_ 2 are hydrogen; R, R_ and R 6 are phosphate, R , R and R 12 are hydroxyl and R. , R κ , R Q , R 1.0- and R. 11. are hydrogen; R_ and R are phosphate, R , R and R are hydroxyl and R, R 4 , R 5 , R g , R 1Q and R 1 are hydrogen; R. R 5 and R are phosphate, R , R and R are hydroxyl and R 4 , R , R , R and R are hydrogen; R 3 and R are phosphate, R 5 , R g and R are hydroxyl and , R 4 , R , R , R and R are hydrogen; , R 3 and R are phosphate, R , R and R are hydroxyl and R 4 , R , R , R and R are hydrogen; R 5 and R are phosphate, R 3 , R and R _ are hydroxyl and R, R , R , R , R and R are hydrogen; R 5 and R χ2 are phosphate, R 3 , R g and R 1Q are hydroxyl and R. , R fi , R_, R and R are hydrogen; R, R 3 and R are phosphate, Rg, R Q and R g are hydroxyl and R. R 4 , 5 , R ? , R 1Q and R 1 are hydrogen; R, R and R g are phosphate, R , R Q and R are hydroxyl and R, R 4 , R 5 , R , R g and R.. are hydrogen; R_ R 5 and R g are phosphate, R χ , R g and R are hydroxyl and R, R 3 , Rg, R 7 , R 1Q and R are hydrogen; R, R 5 and R are phosphate, R , R Q and R are hydroxyl and R-. R 4 , Rg, R y , R g and R χ2 are hydrogen; R and R are phosphate, R , R Q and R are hydroxyl and R, R 4 , R g , R_, R g and R _ are hydrogen; R 3 and R are phosphate, R , R and R are hydroxyl and R 4 , R 6 , R g , R 10 and R χ2 are hydrogen; R, R and R are phosphate, R , R and R are hydroxyl and R 4 , R g , R ? , R 10 and R^ are hydrogen; R, R 3 and R are phosphate, R , R and R are hydroxyl and R, R 4 , R g , R ? , R 1Q and R 1 are hydrogen; R. R 5 and R are phosphate, R , R_ and R are hydroxyl and R 4 , Rg, R γ , R 1Q and R χι are hydrogen; R. R 5 and R g are phosphate, R 3 , R g and R χ2 are hydroxyl and R 4 , R g , R ? , R and R are hydrogen; R , R 5 and R are phosphate, R 3 , R g and R g are hydroxyl and R 4 , Rg, R γ , R 1Q and are hydrogen; R, X and R g are phosphate, R 5 , R g and R 2 are hydroxyl and R 4 , Rg, R ? , R 1(J and R 1 are hydrogen; R, R 5 and R g are phosphate, R χ , R g and R 2 are hydroxyl and R, R 4 , Rg, R ? , R 10 and R lχ are hydrogen; R, R g and R are phosphate, R f R 3 and Rg are hydroxyl and R. R 4 , Rg, R ? , R 1Q and R 1 are hydrogen; R. R and R are phosphate, R , R 5 and R are hydroxyl and R, R 4 , R g , R ? , R 10 and R.. are hydrogen; R 0 8 and R 12 are phosphate, R , R j . and R Q are hydroxyl and R- R 4 , R g , R ? , R - and R are hydrogen; R E R g and R are phosphate, R , R and R are hydroxyl and R , R , R , R and R χ . are hydrogen; R. R g and R are phosphate, R 3 , R g and R„ are hydroxyl and R 4 , R g , R 7 , R_ 0 and R . are hydrogen; R and R are phosphate, R , R and R are hydroxyl and R 4 , Rg, R ? , R 10 and R are hydrogen; R g and R g are phosphate, R 1 , R g and R 1 n 2 are hydroxyl and R, R 4 , Rg, R 7 , R 1Q and R are hydrogen; R g and R_ 2 are phosphate, R , R g and R β are hydroxyl and R, R 4 , R 6 , R ? , R 1Q and ±1 are hydrogen; R, R g and R χ2 are phosphate, R χ , R g and R g are hydroxyl and R_, R 4 , R g , R ? , R χo and R-. are hydrogen; and R 8 , R and R 12 are phosphate, R.^ R 3 and R g are hydroxyl and R 2 , R 4 , Rg, R ? , R 1Q and R 1 are hydrogen. The above formula describes specific isomers of inositol trisphosphate where the inositol is selected from the group myoinositol, cisinositol, epiinositol, alloinositol, neo- inositol, mucoinositol, chiroinositol and scylloinositol. The invention will be further explained in the following examples where Example 1-3 demonstrate the effect of IP to reduce pain in different conditions and where Example 4 shows the manufacturing of a solution of IP for intravenous administration. Example 1 Six patients having disordered gall-bladder (cholecystecto- mized patients) where operated according to standard procedures. After this type of operations most often a one week stay at the hospital follows characterized by pain and gastrointestinal problems. Three of the patients received pentobarbital during and after the operations while three of the patients received an infusion of D-myo-inositol-1.2.6- trisphosphate (IP 3 ) for three days during and after the operation (2 mg IP /kg body weight and hour) . All the patients were asked to indicate the level of pain as a func¬ tion of time on a scale between 0 and 100 where 0 represented no pain. The average value over the three-day period following the operation, the pain-index, was calculated for all the patients. The three patients treated with penta- barbital had a pain index of 35 which is in full agreement with data from many other patients treated in a similar way. The three patients treated with IP had a pain index of 15 for the same period which demonstrates that IP very effectively reduces pain. Futhermore no side-effects or sedative effects could be observed during or after the IP 3 -treatment. Example 2 A total of six patients with rheumatoid arthritis were given an infusion of D-myo-inositol-1.2.6-trisphosphate (IP 3 ) for 48 hours (2 mg/kg/hr) . The pain experienced by each patient was assessed with a pain score ranging from 0 to 10 where a high figure represents a high sense of pain. The average value was 8.4 ± 0.8 before the start of the infusion and after 24 hrs the value was determined to 2.8 ± 0.9. This lower value remained not only during the infusion but also for another twelve days after the infusion was stopped. Thus the results show a quick on-set of the reduction of pain and also a long duration of the analgetic properties after the termination of the administration of the compound. Example 3 Two groups of rats, 10 animals per group, were used in order to investigate the analgetic effect of D-myo-inositol-1.2.6- trisphosphate (IP 3 ) . The control group was given an intravenous dose of saline while the other group was given a dose of 5 mg/kg of the sodium salt of IP 3 - Immediately after intravenous dosing, each rat received an intraperitoneal in¬ jection of 1 ml of a 1 % (w/w) solution of acetic acid. Directly after that procedure each animal was placed into in¬ dividual observation chambers and the numbers of writhes elicited during the subsequent 25-minute period were recorded. After the observation period the animals were killed by cervical dislocation. The number of writhes during the observation period is an expression of the pain experienced by the animal. The control group had an average of 48 writhes during the period while the group receiving IP had an average of 18 writhes during the period. The results demonstrate a significant reduction in pain when IP is administered. Example 4 Solution of sodium salt of D-myo-inositol-1.2.6-trisphosphate (IP ) for injection. 0.5 g of the sodium salt of IP and 0.77 g NaCl were dissolved in 98.73 ml of water for injection to form a solu¬ tion for injection into a person or an animal.

Claims: CLAIMS 1. The use of at least one isomer of inositoltrisphosphate (IP ) for the preparing of a medicament effective as an analgesic. 2. The use of at least one isomer of inositoltrisphosphate ( (IIPP )) ffoorr tthhee pprreeppaarriinngg ooff aa mmedicament for preventing, alleviating or combatting pain 3. The use according to anyone of claims 1-2 wherein said isomer of inositoltrisphosphate is in salt form. 4. The use according to claim 3 wherein said inositoltris¬ phosphate salt is a salt of sodium, potassium, calcium or zinc. 5. The use according to anyone of claims 1-4 wherein the medicament is in unit dosage forms comprising tablets, granules and solutions. 6. The use according to anyone of claims 1-5 wherein said inositoltrisphosphate is D-myo-inositol-1.2.6-trisphos- phate.

Inventors: SIREN MATTI, SIREN, MATTI
Applicants: PERSTORP AB, SIREN MATTI, SIREN, MATTI
Application year: 1993
Main classification: A61K31
IPC codes: A61K31, A61P25